Clinical Trials Browser

Recruiting × Adenocarcinoma × 90 days × Clear all

NCT05065736 2026-03-19

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Phase EARLY_PHASE1 Recruiting

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Neoplasms

NCT06128343 2026-03-19

BACAP-2

Adenocarcinoma, Carcinoma, Neoplasms

NCT06205836 2026-03-17

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT07332000 2026-03-17

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05968326 2026-03-12

IMCODE003

Phase 2 Recruiting

Adenocarcinoma

NCT06901531 2026-03-11

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Adenocarcinoma, Neoplasms

NCT06957691 2026-03-09

Fezo-ADT

Phase 2 Recruiting

EndocrineGenitourinary

Adenocarcinoma, Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1, Hot Flashes

NCT07182279 2026-03-09

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT05873686 2026-03-03

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1 Recruiting

GenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Mesothelioma, Neoplasms

NCT06996249 2026-03-03

DuTOC

12,000 enrolled

Other solid neoplasmThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Mesothelioma, Thymus Neoplasms

NCT04605913 2026-02-25

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT05581121 2026-02-25

PAROLA

Phase 3 Recruiting

Adenocarcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT07124000 2026-02-24

DP-04

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07259317 2026-02-20

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06616597 2026-02-19

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07115914 2026-02-17

PSMA PET for Surveillance After Focal Therapy

Phase NA Recruiting

Adenocarcinoma, Disease, Prostatic Neoplasms

NCT07407608 2026-02-12

ABRUPT 2

Adenocarcinoma, Prostatic Neoplasms

NCT07023315 2026-02-11

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Phase 3 Recruiting

Adenocarcinoma

NCT00349830 2026-02-10

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Adenocarcinoma, Carcinoma, Neoplasms

NCT06561685 2026-02-10

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT06834152 2026-02-09

X-SMILE

Adenocarcinoma, Prostatic Hyperplasia, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT07196488 2026-02-09

Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses

Phase NA Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07391982 2026-02-06

DESTINATION 2

Phase NA Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Phase 1 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07370597 2026-01-27

LUDOPATH

Adenocarcinoma, Prostatic Neoplasms

NCT07363382 2026-01-23

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05208944 2026-01-20

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT07284186 2026-01-16

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07344844 2026-01-15

SPAR

Phase NA Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06592924 2026-01-14

TRIPLE-SWITCH

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07339943 2026-01-14

MicroUSgFLA

Phase NA Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT07129551 2026-01-12

NICE-PSMA

Phase NA Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06801236 2025-12-29

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Adenocarcinoma, Prostatic Neoplasms